Help make a drug to treat post-transplant CMV available to patients in Canada

[CLL_Canada_Group]

If you have experienced Cytomegalovirus (CMV) following your Allogeneic Stem-Cell Transplant, you can help Canadian patients gain access to this treatment by completing our survey! You do not need to live in Canada to complete this survey.

CLL Canada is working with a coalition of blood cancer patient groups to prepare a submission for the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Quebec equivalent INESSS (Institut national d'excellence en santé et services sociaux) for an upcoming drug review on Maribavir, for the treatment of transplant recipients with refractory, with or without resistance (R/R), cytomegalovirus (CMV).

If you have or have had CMV post stem-cell transplant, you can help by completing the survey, whether or not you have received Maribavir as a treatment.

Click here to complete the survey: surveymonkey.com/r/KL2D8XM

This survey provides us with patient input required for the submission. CADTH and INESSS uses this information to help make recommendations to the provinces and territories regarding funding for new cancer drugs.

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

The survey will be open until midnight Pacific Time on February 13, 2022, and should only take between 10-15 minutes of your time.

Click here to complete the survey: surveymonkey.com/r/KL2D8XM

Thank you for participating.